SubHero Banner

Lynparza® (olaparib) – New indication

March 11, 2022 - AstraZeneca announced the FDA approval of Lynparza (olaparib), for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

Download PDF